Medicare Drug Price Negotiations Secure Deeper Discounts in Second Year, With Potential Medicaid Spillover Effects

CMS achieved an average 62% discount off list prices for 15 drugs in the second cohort of Medicare drug price negotiations, representing a 28% reduction below statutory ceiling prices—nearly double the discount margin achieved in year one. While the negotiation program is Medicare-focused, the outcomes have implications for Medicaid managed care organizations through potential manufacturer price adjustments, best price calculations, and rebate dynamics that could affect MCO pharmacy budgets and formulary strategies. The deeper discounts may also influence cross-program pricing pressure and state supplemental rebate negotiations.

Pharmacy

This is outside commentary from Manatt Health, not part of Medicaid Monitor's independently scored news coverage.

More from Manatt Health